Coherus Oncology Inc. (CHRS)
CHRS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.07
+3.88% on the day
Market cap
$165.3M
Micro cap
Revenue · 2025
$42.2M
No prior year to compare
Net income · 2025
$168.0M
398.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/0001104659-26-025308-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CHRS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001512762 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $42.2M |
| Net income | $168.0M |
| Operating income | -$181.1M |
| Net margin | 398.4% |
| Operating margin | -429.5% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $88.9M |
| Total assets | $258.3M |
| P/E (computed) | 1.0× |
| P/S (computed) | 3.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-28 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-08-28 |
| Latest proxy | DEFA14A | 2026-05-28 |
Source: SEC EDGAR submissions feed, 920 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IPHA | Innate Pharma S.A. ADS | $1.47 | -0.68% | $164.2M |
| DTIL | Precision BioSciences Inc. | $6.10 | -6.58% | $168.4M |
| TARA | Protara Therapeutics Inc. | $2.62 | -5.42% | $154.8M |
| CMPX | Compass Therapeutics Inc. | $0.8570 | -8.59% | $154.3M |
| STRO | Sutro Biopharma Inc. | $11.01 | -17.09% | $182.6M |
| CGEN | Compugen Ltd. | $1.98 | -4.35% | $187.3M |
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $1.20 | +1.70% | $144.8M |
| IVVD | Invivyd Inc. | $0.6460 | -4.05% | $190.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier